Enforcement committee flags underreporting, recommends standardized ADDS QA template and clearer inspection communications

The board's Enforcement & Compounding Committee presented annual summaries of its inspection program and citation activity and reported on the board's review of quality assurance (QA) reports tied to automated drug delivery systems (ADDS).

Inspectors and staff described progress toward the board’s strategic objective of inspecting every licensed pharmacy within a four‑year cycle. Committee members commended inspectors for reaching the goal and requested that next year’s presentation break down inspection data by license type, and include plain language definitions (for example, “order of correction” vs. “written notice”) attached to inspection reports so licensees clearly understand outcomes and next steps.

The committee also reviewed citation trends and noted a decline in total citations for FY24‑25 while staff continue internal norming. Members suggested additional inspector‑facing materials and consumer education to clarify terminology and expectations.

A major focus was on ADDS QA reporting. The board receives annual QA reports under 16 CCR §1711(f) and submitted a January 2025 report to the legislature per Business & Professions Code §4427.8. Staff told the committee the board is still seeing significant underreporting of ADDS QA events and that many QA submissions lack essential data elements (for example, whether the error involved wrong medication, wrong dose, unauthorized access, or system vs. human cause). The committee recommended staff develop a standardized reporting template and consider revising ADDS FAQs and outreach so licensees better understand when and how to report.

Public commenters, including hospital and health‑system pharmacists, urged the board to focus on collecting actionable data—data elements that help determine root cause and whether safety parameters in devices were bypassed. Commenters also asked the board to coordinate with device manufacturers and health systems to improve data export and analytic capabilities. Some commenters raised concerns about the interplay between QA reports and protected peer‑review materials; staff clarified that QA reports to the board do not require patient‑identifying data.

Committee action and follow up: members recommended the development of an ADDS QA template and FAQs; staff will propose outreach and a possible inspector supplemental checklist to improve data quality and consistency. The committee also recommended that inspection reports include an attached glossary or fact sheet explaining inspection terminology for licensees.

Why it matters: inconsistent reporting and missing data elements hinder the board’s ability to analyze ADDS‑related medication errors and to determine whether errors stem from technology, access controls, staffing, or other causes. Better‑structured QA reports will enable targeted education, inspections, and potential policy changes to reduce medication errors.

What’s next: staff will draft a standardized ADDS QA template for committee review and produce suggestions for revised FAQs and inspector guidance. The committee plans to revisit the topic after additional outreach and data collection.